TGTX(TG Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $6.69M | $2.79M | $233.66M | $329.00M | $616.29M |
| 毛利润 | $5.90M | $2.52M | $219.53M | $290.52M | $515.57M |
| 营业利润 | −$344.77M | −$218.32M | $20.63M | $41.93M | $123.32M |
| 净利润 | −$348.10M | −$223.81M | $12.67M | $23.38M | $447.18M |
| 经营现金流 | −$295.63M | −$176.17M | −$31.41M | −$40.52M | −$24.77M |
| 自由现金流 | −$296.04M | −$176.18M | −$31.41M | −$40.56M | −$24.99M |
| 摊薄每股收益 | $-2.63 | $-1.65 | $0.09 | $0.15 | $2.77 |